General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
HIV-1 Infection
Last updated June 25, 2026
Status:
Concluded with an LOI
Manufacturer:
Cipher
Indication:
Acne Vulgaris
Last updated June 25, 2026
Name to be determined (ranibizumab)
Status:
Active negotiation
Manufacturer:
Sandoz Canada Inc.
Indication:
Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Last updated June 17, 2026
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.
Last updated June 16, 2026
Status:
Concluded without agreement
Manufacturer:
Biogen Canada Inc.
Indication:
Friedreich's ataxia
Last updated June 10, 2026
Status:
Negotiations were not pursued
Manufacturer:
Arcutis Biotherapeutics, Inc.
Indication:
Atopic dermatitis
Last updated June 5, 2026
Status:
Negotiations were not pursued
Manufacturer:
Amgen Canada Inc.
Indication:
Thyroid Eye Disease
Last updated June 5, 2026
Zepzelca (pTAP negotiation) (lurbinectedin)
Status:
Concluded without agreement
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.
Last updated June 3, 2026
Status:
Concluded without agreement
Manufacturer:
Teva Canada Innovation
Indication:
Schizophrenia in Adults
Last updated May 29, 2026
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
In combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor-positive (HR+) (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.
Last updated May 26, 2026